Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tomonubu Koizumi"'
Autor:
Paul Workman, Mike Waterfield, Peter Parker, Nahid Saghir, Sonal Patel, Takahide Ohishi, Tomonubu Koizumi, Hiroyuki Kaizawa, Masahiko Hayakawa, Alexis de Haven Brandon, Sharon Gowan, Lisa Patterson, Melanie Valenti, Lloyd Kelland, Lynn M. Bjerke, Sandrine Guillard, Zahida Ahmad, Francesca Di-Stefano, Alan Henley, Sonia Alix, Bernard Nutley, Angela Hayes, Paul A. Clarke, Suzanne Eccles, Florence I. Raynaud
Supplementary Figures 1-2 from Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::369ce14b8c8801f9d9e672b7bbcbaba5
https://doi.org/10.1158/0008-5472.22367580
https://doi.org/10.1158/0008-5472.22367580
Autor:
Paul Workman, Mike Waterfield, Peter Parker, Nahid Saghir, Sonal Patel, Takahide Ohishi, Tomonubu Koizumi, Hiroyuki Kaizawa, Masahiko Hayakawa, Alexis de Haven Brandon, Sharon Gowan, Lisa Patterson, Melanie Valenti, Lloyd Kelland, Lynn M. Bjerke, Sandrine Guillard, Zahida Ahmad, Francesca Di-Stefano, Alan Henley, Sonia Alix, Bernard Nutley, Angela Hayes, Paul A. Clarke, Suzanne Eccles, Florence I. Raynaud
Supplementary Figure Legends 1-2 from Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fcf46806cab9a2ae2886c96269f2566
https://doi.org/10.1158/0008-5472.22367583.v1
https://doi.org/10.1158/0008-5472.22367583.v1
Autor:
Paul Workman, Mike Waterfield, Peter Parker, Nahid Saghir, Sonal Patel, Takahide Ohishi, Tomonubu Koizumi, Hiroyuki Kaizawa, Masahiko Hayakawa, Alexis de Haven Brandon, Sharon Gowan, Lisa Patterson, Melanie Valenti, Lloyd Kelland, Lynn M. Bjerke, Sandrine Guillard, Zahida Ahmad, Francesca Di-Stefano, Alan Henley, Sonia Alix, Bernard Nutley, Angela Hayes, Paul A. Clarke, Suzanne Eccles, Florence I. Raynaud
Extensive evidence implicates activation of the lipid phosphatidylinositide 3-kinase (PI3K) pathway in the genesis and progression of various human cancers. PI3K inhibitors thus have considerable potential as molecular cancer therapeutics. Here, we d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b472982bf29403e67404aaf425b7207
https://doi.org/10.1158/0008-5472.c.6495612.v1
https://doi.org/10.1158/0008-5472.c.6495612.v1
Autor:
Paul A. Clarke, Sharon Gowan, Takahide Ohishi, Lisa Patterson, Zahida Ahmad, Melanie Valenti, Sonia Alix, Mike Waterfield, Bernard Nutley, Peter J. Parker, Sonal Patel, Tomonubu Koizumi, Hiroyuki Kaizawa, Nahid Saghir, Alexis De Haven Brandon, Florence I. Raynaud, Angela Hayes, Masahiko Hayakawa, Sandrine Guillard, Francesca Di-Stefano, Paul Workman, Alan T. Henley, Lloyd R. Kelland, Lynn Bjerke, Suzanne A. Eccles
Publikováno v:
Cancer research. 67(12)
Extensive evidence implicates activation of the lipid phosphatidylinositide 3-kinase (PI3K) pathway in the genesis and progression of various human cancers. PI3K inhibitors thus have considerable potential as molecular cancer therapeutics. Here, we d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5d3c9e38baa80c6adfe4f28f7a5858
https://pubmed.ncbi.nlm.nih.gov/17575152
https://pubmed.ncbi.nlm.nih.gov/17575152
